Endocrinology

The development of recombinant DNA technology has brought about the large-scale availability of biosynthetic human growth hormone for treatment of pediatric growth disorders. Children receiving Genotropin therapy will be followed on a long-term basis to assess the long-term safety and growth response to this therapy. The collection of these data will be integrated into the international database.

Inclusion criteria

• Children being treated with Genotropin for a growth disorder.

Exclusion criteria

• Subjects with closed epiphyses and those with active malignancies.

What is expected of me and my child?

Collection of data will be done following scheduled clinic visits for routine endocrine care. Data will be entered via a secure web site.

• Hershey Medical Center outpatient clinics.